MET and non-small cell lung carcinoma: According to data for the Korean NSCLC patients' group (Ji et al., 2013[37]), the coexistence of T790M mutation and MET amplification was found in 11.5 % of patients, and almost the same result was obtained for the group with only MET alteration.